A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Next Cure, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 400,400 shares of NXTC stock, worth $616,616. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400,400
Previous 293,315 36.51%
Holding current value
$616,616
Previous $334,000 167.37%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.13 - $2.23 $121,006 - $238,799
107,085 Added 36.51%
400,400 $893,000
Q4 2023

Feb 13, 2024

BUY
$1.03 - $1.45 $44,408 - $62,516
43,115 Added 17.23%
293,315 $334,000
Q3 2023

Nov 14, 2023

BUY
$1.29 - $1.84 $3,870 - $5,520
3,000 Added 1.21%
250,200 $323,000
Q2 2023

Aug 11, 2023

BUY
$1.47 - $1.86 $3,969 - $5,022
2,700 Added 1.1%
247,200 $445,000
Q1 2023

May 12, 2023

SELL
$1.46 - $1.83 $236,644 - $296,615
-162,085 Reduced 39.86%
244,500 $362,000
Q4 2022

Feb 13, 2023

BUY
$1.2 - $2.49 $211,902 - $439,696
176,585 Added 76.78%
406,585 $573,000
Q3 2022

Nov 14, 2022

SELL
$2.97 - $5.19 $183,379 - $320,451
-61,744 Reduced 21.16%
230,000 $633,000
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.27 $483,150 - $753,314
142,944 Added 96.06%
291,744 $1.37 Million
Q1 2022

May 13, 2022

BUY
$4.76 - $6.24 $186,592 - $244,608
39,200 Added 35.77%
148,800 $723,000
Q4 2021

Feb 11, 2022

SELL
$5.7 - $9.1 $1.51 Million - $2.41 Million
-264,500 Reduced 70.7%
109,600 $658,000
Q3 2021

Nov 12, 2021

BUY
$6.74 - $8.02 $1.17 Million - $1.39 Million
173,800 Added 86.77%
374,100 $2.52 Million
Q2 2021

Aug 13, 2021

BUY
$7.6 - $10.28 $1.52 Million - $2.06 Million
200,300 New
200,300 $1.61 Million
Q3 2020

Nov 13, 2020

SELL
$8.15 - $21.17 $522,415 - $1.36 Million
-64,100 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$21.19 - $40.2 $1.36 Million - $2.58 Million
64,100 New
64,100 $1.37 Million

Others Institutions Holding NXTC

About NextCure, Inc.


  • Ticker NXTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,748,800
  • Market Cap $42.7M
  • Description
  • NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...
More about NXTC
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.